沙美特罗/福替卡松对中重度慢阻肺患者稳定期临床疗效的观察  

Effect of the Salmeterol/Fluticasone powder inhalationaltreatment on acute exacerbation phase blood gases at the stable phase of chronic obstructive pulmonary disease

作　　者：刘燕[1] 晋小祥[1] 金邦贤[1] 

机构地区：[1]安徽省马鞍山市中心医院呼吸科,安徽马鞍山243000

出　　处：《安徽医药》2013年第1期120-122,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：目的观察沙美特罗/福替卡松(商品名:舒利迭50/500μg)在中重度慢阻肺患者稳定期治疗中的临床疗效。方法 60例中重度慢阻肺患者随机分成对照组和观察组,两组均予以抗感染、化痰、氨茶碱基础治疗,在此基础上,对照组患者予以加口服泼尼松龙40 mg qd,观察组患者予以沙美特罗/福替卡松(商品名:舒利迭50/500μg)吸入治疗Bid,观察治疗第7、14天的肺功能和血气分析结果。结果两组患者治疗第7天与治疗前相比,肺功能和血气分析结果变化均有明显改善,其差异有统计学意义P<0.01,治疗第7天对照组与观察组肺功能和血气分析结果差异无统计学意义P>0.05,观察组治疗第14天与对照组肺功能血气分析结果差异无统计学意义P>0.05。结论舒利迭50/500μg对中重度慢阻肺患者临床疗效与全身使用糖皮质激素差异无统计学意义,对中重度慢性阻塞性肺疾病(COPD)治疗有益能够加快病情缓解改善肺功能FEV1和低氧血症,且副作用相对小。Objective To discuss the effect of Salmeterol/Fluticasone powder inhalational treatment on acute exacerbation phase blood gases at the stable phase of chronic obstructive pulmonarydisease（COPD）.Methods 60 patients were divided into two groups：thirty cases of middle and advanced COPD patients who had never received the combination therapy of the inhalational glucocorticoid and long-acting receptor stimulant were treated with Salmeterol/Fluticasone powder inhalation（retiedde）until admitted to hospital again due to the occurrence of acute exacerbation chronic obstructive pulmonary disease（AECOPD）.Thirty cases of middle and advanced COPD patients were treated in the rountine way.A comparison of pH.arterial partial pressure of oxygen（PaOz）and arterial partial pressure of carbondioxide（PaCOz） was made.Results The difference in pulmonary function was statistically significant between before and after the treatment（P0.01）.The difference between the two groups after the treatment was not statistically significant（P0.05）.Conclusions The inhalation of Salmeterol 50/500 μg compound preparation at the middle and advanced COPD stable phase will significantly improve the patients＂condition and blood gases during the AECOPD.

关 键 词：沙美特罗 福替卡松 慢性阻塞性肺疾病 血气 

分 类 号：R563.9[医药卫生—呼吸系统]